Company officials discuss status of FDA external review contract with CDER Deputy Director Gerald Meyer at June 16 meeting. FDA is being asked by the Bedford, Mass.-company about the continuation of the external review project after the expected increase in FDA's internal review capacity from user fee funding. Mitre has completed review of two efficacy supplements for the agency and is working on a third under a $221,608 contract signed Sept. 24, 1992.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth